- Home
- CANF vs HSCS Comparison
CANF vs HSCS Comparison
Compare CANF & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- HSCS
- Stock Information
- Founded
- CANF 1994
- HSCS 2007
- Country
- CANF Israel
- HSCS United States
- Employees
- CANF N/A
- HSCS N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- HSCS Medical Specialities
- Sector
- CANF Health Care
- HSCS Health Care
- Exchange
- CANF Nasdaq
- HSCS Nasdaq
- Market Cap
- CANF 9.6M
- HSCS 9.9M
- IPO Year
- CANF N/A
- HSCS 2022
- Fundamental
- Price
- CANF $0.50
- HSCS $3.37
- Analyst Decision
- CANF Strong Buy
- HSCS Strong Buy
- Analyst Count
- CANF 2
- HSCS 2
- Target Price
- CANF $14.50
- HSCS $10.50
- AVG Volume (30 Days)
- CANF 280.9K
- HSCS 40.3K
- Earning Date
- CANF 11-27-2025
- HSCS 09-11-2025
- Dividend Yield
- CANF N/A
- HSCS N/A
- EPS Growth
- CANF N/A
- HSCS N/A
- EPS
- CANF N/A
- HSCS N/A
- Revenue
- CANF $560,000.00
- HSCS $6,250.00
- Revenue This Year
- CANF $461.72
- HSCS N/A
- Revenue Next Year
- CANF N/A
- HSCS N/A
- P/E Ratio
- CANF N/A
- HSCS N/A
- Revenue Growth
- CANF N/A
- HSCS N/A
- 52 Week Low
- CANF $0.47
- HSCS $2.52
- 52 Week High
- CANF $3.02
- HSCS $6.47
- Technical
- Relative Strength Index (RSI)
- CANF 31.15
- HSCS 44.37
- Support Level
- CANF $0.49
- HSCS $3.29
- Resistance Level
- CANF $0.55
- HSCS $3.45
- Average True Range (ATR)
- CANF 0.03
- HSCS 0.16
- MACD
- CANF -0.00
- HSCS -0.03
- Stochastic Oscillator
- CANF 13.94
- HSCS 34.43
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.